Transforming Lives

Through a new class of safe, durable cancer treatments.

Our Team

Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.
Learn more
Our Science

Our approach uses a new class of compounds called imipridones to selectively target G protein-coupled receptors (GPCRs) that control critical signaling pathways in cancer.
Learn more
Alliances

MD Anderson Cancer Center and Massachusetts General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.
Learn more

- OCT 09 2020
DRD2-mediated preclinical efficacy of ONC201 in endometrial cancer
DRD2 is overexpressed in endometrial cancer and confers poor prognosis. DRD2 antagonism by ONC201 elicits efficacy in an endometrial cancer genetic mouse model. Please find the full paper here.

Read >

- AUG 31 2020
New Biomarker of Glioblastoma Response to ONC201
Glioblastoma with low EGFR expression tends to have high DRD2 expression and be more responsive to ONC201. Please find the full manuscript here.

Read >